FLYER: Phase III Trial of R-CHOP x 4 Followed by Rituximab x 2 vs R-CHOP x 6 in Younger Patients With Favorable-Prognosis DLBCL

Source: 2018 American Society of Hematology Annual Meeting*
Download Slideset
December 1-4, 2018; San Diego, California
Efficacy with R-CHOP x 4 → R x 2 was noninferior to R-CHOP x 6 with a decrease in the number of nonhematologic adverse events by approximately one third.
Format: Microsoft PowerPoint (.ppt)
File Size: 216 KB
Released: December 3, 2018

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower.
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Incyte
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Seagen
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings